trending Market Intelligence /marketintelligence/en/news-insights/trending/qeefVIJ2ysH3GCS1PyovhA2 content esgSubNav
In This List

Admedus completes sale of part of infusion business to BTC for A$6.3M

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Admedus completes sale of part of infusion business to BTC for A$6.3M

Admedus Ltd. completed the sale of a portion of its infusion business to BTC Health Ltd. for about A$6.3 million.

The divestment — part of the Australian healthcare supplies company's restructuring plan — does not include the rights to the Arcomed and Leventon range of infusion pumps, which remain with Admedus. The sale will allow the company to pursue its global growth strategy to focus on the commercial growth and development of its Adapt product portfolio.

BTC, a venture capital fund focused on the healthcare sector, previously said the deal will include the replacement of an old contract with a new eight-year exclusive distribution agreement with Summit Medical Products for the ambIT range of infusion pumps in Australia and New Zealand, and purchase of all salable inventory.

The fund intends to finance the acquisition through a two-tranche private placement and a share buyback plan.